{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 106 of 128', 'Appendix 1: Definitions of adverse events and serious adverse events', 'Adverse event definition', 'An AE is defined as any untoward medical occurrence in a patient or clinical investigation', 'subject administered a pharmaceutical product and which does not necessarily have a causal', 'relationship with this treatment. An AE can therefore be any unfavourable and unintended', 'sign (including an abnormal laboratory finding), symptom, or disease temporally associated', 'with the use of a medicinal (investigational) product, whether or not related to the medicinal', '(investigational) product. (ICH Harmonized Tripartite Guideline for Good Clinical Practice,', 'E6 (R1)).', 'This definition includes:', 'Accidental injuries.', 'Events related to trial procedures.', 'Reasons for any unfavourable and unplanned change in medication (drug', 'and/or dose).', 'Clinically significant worsening of pre-existing conditions.', 'Reasons for admission to hospital or surgical procedures unless these were', 'planned before the subject consented to trial participation.', 'AEs commonly observed, and AEs anticipated based on the pharmacological', 'effect of the IMP.', 'Any laboratory abnormality assessed as clinically significant by the', 'investigator (see Section 11.4.4).', 'Serious adverse event definition', 'An SAE is any untoward medical occurrence that', 'Results in death.', 'Is life-threatening.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 107 of 128', 'Requires inpatient hospitalisation or prolongation of existing hospitalisation.', 'Planned hospitalisation or planned prolonged hospitalisation do not fulfil the', \"criteria for being an SAE but should be documented in the subject's medical\", 'record.', 'Results in persistent or significant disability/incapacity.', 'Is a congenital anomaly/birth defect.', 'or', 'Is a medically important condition. Events that may not be immediately', 'life-threatening or result in death or hospitalisation but may jeopardise the', 'subject or may require intervention to prevent one of the other outcomes listed', 'in the definition above. Examples are intensive treatment in an emergency', 'room or at home for allergic broncospasm, blood dyscrasias and convulsions', 'that do not result in hospitalisation, development of drug dependency or drug', 'abuse.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 108 of 128', 'Appendix 2: Classification of adverse events', 'Severity', 'The severity of the AE should be described in terms of mild, moderate or severe according to', \"the investigator's clinical judgement.\", 'Mild', 'An AE that is usually transient and may require only minimal treatment or', 'therapeutic intervention. The event does not generally interfere with usual', 'activities of daily living.', 'Moderate', 'An AE that is usually alleviated with additional specific therapeutic', 'intervention. The event interferes with usual activities of daily living,', 'causing discomfort but poses no significant or permanent risk of harm to the', 'subject.', 'Severe', 'An AE that interrupts usual activities of daily living, or significantly affects', 'clinical status, or may require intensive therapeutic intervention.', 'If the severity of an AE worsens, a new AE should be recorded.', 'Causality', 'The causal relation of the AE to the use of the IMP should be described in terms of probably,', \"possibly, or not related according to the investigator's clinical judgement. The categories are\", 'defined below.', 'Probably', 'Follows a reasonable temporal sequence from administration of the IMP.', 'related', \"Could not be reasonably explained by the subject's clinical state,\", 'environmental or toxic factors or other therapies administered to the', 'subject.', 'Follows a known pattern of response to the IMP.', 'Disappears or decreases on cessation or reduction in dose of the IMP.', 'Reappears or worsens upon re-challenge.']\n\n###\n\n", "completion": "END"}